Details of the Drug

General Information of Drug (ID: DM2AQ5N)

Drug Name
Spironolactone
Synonyms
Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
Indication
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [1]
Congestive heart failure BD10 Approved [2]
Edema MG29 Approved [1]
Hyperaldosteronism 5A72 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Therapeutic Class
Diuretics
Affected Organisms
Humans and other mammals
ATC Code
C03DA01: Spironolactone
C03DA: Aldosterone antagonists
C03D: ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03: DIURETICS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 416.6
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.71714 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.022 mg/mL [4]
Chemical Identifiers
Formula
C24H32O4S
IUPAC Name
S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
Canonical SMILES
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
InChI
InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChIKey
LXMSZDCAJNLERA-ZHYRCANASA-N
Cross-matching ID
PubChem CID
5833
ChEBI ID
CHEMBL1393
CAS Number
52-01-7
UNII
27O7W4T232
DrugBank ID
DB00421
TTD ID
D0EP0C
VARIDT ID
DR00609
ACDINA ID
D00638
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mineralocorticoid receptor (MR) TT26PHO MCR_HUMAN Modulator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [7]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [8]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Gene/Protein Processing [9]
Myb-related protein A (MYBL1) OTBJMC2P MYBA_HUMAN Gene/Protein Processing [10]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Gene/Protein Processing [9]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Gene/Protein Processing [9]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Gene/Protein Processing [11]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Gene/Protein Processing [10]
Renin (REN) OT52GZR2 RENI_HUMAN Drug Response [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic heart failure
ICD Disease Classification BD1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mineralocorticoid receptor (MR) DTT NR3C2 7.31E-01 -5.31E-04 -1.53E-03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Spironolactone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eplerenone DMF0NQR Major Increased risk of hyperkalemia by the combination of Spironolactone and Eplerenone. Heart failure [BD10-BD1Z] [13]
Carvedilol DMHTEAO Moderate Increased risk of hyperglycemia by the combination of Spironolactone and Carvedilol. Heart failure [BD10-BD1Z] [14]
Amiloride DMRTSGP Major Increased risk of hyperkalemia by the combination of Spironolactone and Amiloride. Heart failure [BD10-BD1Z] [15]
Coadministration of a Drug Treating the Disease Different from Spironolactone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Idarubicin DMM0XGL Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [16]
Daunorubicin DMQUSBT Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Moderate Decreased metabolism of Spironolactone caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [17]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Spironolactone and Linezolid. Bacterial infection [1A00-1C4Z] [18]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Spironolactone and Cariprazine. Bipolar disorder [6A60] [19]
Loperamide DMOJZQ9 Major Decreased clearance of Spironolactone due to the transporter inhibition by Loperamide. Bowel habit change [ME05] [20]
Talazoparib DM1KS78 Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [21]
Bosutinib DMTI8YE Moderate Decreased metabolism of Spironolactone caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [17]
Sotalol DML60TN Moderate Increased risk of hypertriglyceridemia by the combination of Spironolactone and Sotalol. Cardiac arrhythmia [BC9Z] [14]
Pentosan polysulfate DM2HRKE Moderate Increased risk of hyperkalemia by the combination of Spironolactone and Pentosan polysulfate. Chronic pain [MG30] [22]
Phenylbutazone DMAYL0T Moderate Antagonize the effect of Spironolactone when combined with Phenylbutazone. Chronic pain [MG30] [23]
Ketoprofen DMRKXPT Moderate Antagonize the effect of Spironolactone when combined with Ketoprofen. Chronic pain [MG30] [23]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Spironolactone and Levomilnacipran. Chronic pain [MG30] [24]
Fidaxomicin DMFP6MV Minor Decreased clearance of Spironolactone due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [25]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Spironolactone and Olopatadine. Conjunctiva disorder [9A60] [26]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Spironolactone and Drospirenone. Contraceptive management [QA21] [27]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Spironolactone and Ardeparin. Coronary thrombosis [BA43] [17]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Spironolactone and Sertraline. Depression [6A70-6A7Z] [24]
Fluoxetine DM3PD2C Moderate Increased risk of hyponatremia by the combination of Spironolactone and Fluoxetine. Depression [6A70-6A7Z] [24]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Spironolactone and Vilazodone. Depression [6A70-6A7Z] [24]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Spironolactone and Paroxetine. Depression [6A70-6A7Z] [24]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Spironolactone and Selegiline. Depression [6A70-6A7Z] [18]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Spironolactone and Vortioxetine. Depression [6A70-6A7Z] [24]
Duloxetine DM9BI7M Moderate Increased risk of hyponatremia by the combination of Spironolactone and Duloxetine. Depression [6A70-6A7Z] [24]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Spironolactone and Isocarboxazid. Depression [6A70-6A7Z] [18]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Spironolactone and Milnacipran. Depression [6A70-6A7Z] [24]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Spironolactone and Escitalopram. Depression [6A70-6A7Z] [24]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Spironolactone and Tranylcypromine. Depression [6A70-6A7Z] [18]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Spironolactone and Desvenlafaxine. Depression [6A70-6A7Z] [24]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Spironolactone and OPC-34712. Depression [6A70-6A7Z] [19]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Spironolactone and Phenelzine. Depression [6A70-6A7Z] [18]
Carbamazepine DMZOLBI Moderate Increased risk of hyponatremia by the combination of Spironolactone and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [28]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Spironolactone and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [29]
Nadolol DMW6GVL Moderate Increased risk of ventricular arrhythmias by the combination of Spironolactone and Nadolol. Essential hypertension [BA00] [14]
Mefenamic acid DMK7HFI Moderate Antagonize the effect of Spironolactone when combined with Mefenamic acid. Female pelvic pain [GA34] [23]
Ripretinib DM958QB Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [30]
Carteolol DMFMDOB Moderate Increased risk of ventricular arrhythmias by the combination of Spironolactone and Carteolol. Glaucoma [9C61] [14]
Metipranolol DMJMVKI Moderate Increased risk of ventricular arrhythmias by the combination of Spironolactone and Metipranolol. Glaucoma [9C61] [14]
Levobunolol DMTNFCQ Moderate Increased risk of hyperglycemia by the combination of Spironolactone and Levobunolol. Glaucoma [9C61] [14]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Spironolactone and Procarbazine. Hodgkin lymphoma [2B30] [18]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [31]
Fostemsavir DM50ILT Moderate Decreased metabolism of Spironolactone caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Spironolactone and Eprosartan. Hypertension [BA00-BA04] [33]
Acebutolol DM0TI4U Moderate Increased risk of hypertriglyceridemia by the combination of Spironolactone and Acebutolol. Hypertension [BA00-BA04] [14]
Aliskiren DM1BV7W Moderate Increased risk of hyperkalemia by the combination of Spironolactone and Aliskiren. Hypertension [BA00-BA04] [34]
Moexipril DM26E4B Major Increased risk of hyperkalemia by the combination of Spironolactone and Moexipril. Hypertension [BA00-BA04] [35]
Bisoprolol DM3UZ95 Moderate Increased risk of hypertriglyceridemia by the combination of Spironolactone and Bisoprolol. Hypertension [BA00-BA04] [14]
Captopril DM458UM Major Increased risk of hyperkalemia by the combination of Spironolactone and Captopril. Hypertension [BA00-BA04] [35]
Trandolapril DM4L6EU Major Increased risk of hyperkalemia by the combination of Spironolactone and Trandolapril. Hypertension [BA00-BA04] [35]
Losartan DM72JXH Major Increased risk of hyperkalemia by the combination of Spironolactone and Losartan. Hypertension [BA00-BA04] [33]
Nebivolol DM7F1PA Moderate Increased risk of hyperglycemia by the combination of Spironolactone and Nebivolol. Hypertension [BA00-BA04] [14]
Fosinopril DM9NJ52 Major Increased risk of hyperkalemia by the combination of Spironolactone and Fosinopril. Hypertension [BA00-BA04] [35]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Spironolactone and TAK-491. Hypertension [BA00-BA04] [33]
Pindolol DMD2NV7 Moderate Increased risk of hyperglycemia by the combination of Spironolactone and Pindolol. Hypertension [BA00-BA04] [14]
Benazepril DMH1M9B Major Increased risk of hyperkalemia by the combination of Spironolactone and Benazepril. Hypertension [BA00-BA04] [35]
Labetalol DMK8U72 Moderate Increased risk of hyperglycemia by the combination of Spironolactone and Labetalol. Hypertension [BA00-BA04] [14]
Enalapril DMNFUZR Major Increased risk of hyperkalemia by the combination of Spironolactone and Enalapril. Hypertension [BA00-BA04] [35]
Perindopril DMOPZDT Major Increased risk of hyperkalemia by the combination of Spironolactone and Perindopril. Hypertension [BA00-BA04] [35]
Quinapril DMR8H31 Major Increased risk of hyperkalemia by the combination of Spironolactone and Quinapril. Hypertension [BA00-BA04] [35]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Spironolactone and Telmisartan. Hypertension [BA00-BA04] [33]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Spironolactone and Irbesartan. Hypertension [BA00-BA04] [33]
Lisinopril DMUOK4C Major Increased risk of hyperkalemia by the combination of Spironolactone and Lisinopril. Hypertension [BA00-BA04] [35]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Spironolactone and Potassium chloride. Hypo-kalaemia [5C77] [36]
Tolvaptan DMIWFRL Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [37]
Meclofenamic acid DM05FXR Moderate Antagonize the effect of Spironolactone when combined with Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [23]
Berotralstat DMWA2DZ Major Decreased clearance of Spironolactone due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [38]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Spironolactone and Propiomazine. Insomnia [7A00-7A0Z] [19]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Spironolactone and ITI-007. Insomnia [7A00-7A0Z] [19]
GDC-0199 DMH0QKA Major Decreased clearance of Spironolactone due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [30]
Ubrogepant DM749I3 Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Ubrogepant. Migraine [8A80] [39]
Propranolol DM79NTF Moderate Increased risk of ventricular arrhythmias by the combination of Spironolactone and Propranolol. Migraine [8A80] [14]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Spironolactone and Ozanimod. Multiple sclerosis [8A40] [18]
Romidepsin DMT5GNL Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [40]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Spironolactone and Prochlorperazine. Nausea/vomiting [MD90] [19]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Spironolactone and Promethazine. Nausea/vomiting [MD90] [19]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Spironolactone and Sibutramine. Obesity [5B80-5B81] [24]
S-297995 DM26IH8 Moderate Decreased metabolism of Spironolactone caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [17]
Rofecoxib DM3P5DA Moderate Antagonize the effect of Spironolactone when combined with Rofecoxib. Osteoarthritis [FA00-FA05] [23]
Valdecoxib DMAY7H4 Moderate Antagonize the effect of Spironolactone when combined with Valdecoxib. Osteoarthritis [FA00-FA05] [23]
Diclofenac DMPIHLS Moderate Antagonize the effect of Spironolactone when combined with Diclofenac. Osteoarthritis [FA00-FA05] [23]
Naproxen DMZ5RGV Moderate Antagonize the effect of Spironolactone when combined with Naproxen. Osteoarthritis [FA00-FA05] [23]
MK-4827 DMLYGH4 Moderate Decreased clearance of Spironolactone due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [41]
Etodolac DM6WJO9 Moderate Antagonize the effect of Spironolactone when combined with Etodolac. Pain [MG30-MG3Z] [23]
Diflunisal DM7EN8I Moderate Antagonize the effect of Spironolactone when combined with Diflunisal. Pain [MG30-MG3Z] [23]
Ibuprofen DM8VCBE Moderate Antagonize the effect of Spironolactone when combined with Ibuprofen. Pain [MG30-MG3Z] [23]
Nabumetone DMAT2XH Moderate Antagonize the effect of Spironolactone when combined with Nabumetone. Pain [MG30-MG3Z] [23]
Piroxicam DMTK234 Moderate Antagonize the effect of Spironolactone when combined with Piroxicam. Pain [MG30-MG3Z] [23]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Spironolactone and Safinamide. Parkinsonism [8A00] [18]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Spironolactone and Rasagiline. Parkinsonism [8A00] [18]
Lefamulin DME6G97 Moderate Decreased metabolism of Spironolactone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [42]
Ketorolac DMI4EL5 Moderate Antagonize the effect of Spironolactone when combined with Ketorolac. Postoperative inflammation [1A00-CA43] [23]
Bromfenac DMKB79O Moderate Antagonize the effect of Spironolactone when combined with Bromfenac. Postoperative inflammation [1A00-CA43] [23]
Relugolix DMK7IWL Major Decreased clearance of Spironolactone due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [43]
Silodosin DMJSBT6 Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [44]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Spironolactone and Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Spironolactone and Fluphenazine. Psychotic disorder [6A20-6A25] [19]
Triflupromazine DMKFQJP Moderate Additive hypotensive effects by the combination of Spironolactone and Triflupromazine. Psychotic disorder [6A20-6A25] [19]
Riociguat DMXBLMP Moderate Decreased metabolism of Spironolactone caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [30]
Meloxicam DM2AR7L Moderate Antagonize the effect of Spironolactone when combined with Meloxicam. Rheumatoid arthritis [FA20] [23]
Sulindac DM2QHZU Moderate Antagonize the effect of Spironolactone when combined with Sulindac. Rheumatoid arthritis [FA20] [23]
Celecoxib DM6LOQU Moderate Antagonize the effect of Spironolactone when combined with Celecoxib. Rheumatoid arthritis [FA20] [23]
Oxaprozin DM9UB0P Moderate Antagonize the effect of Spironolactone when combined with Oxaprozin. Rheumatoid arthritis [FA20] [23]
Flurbiprofen DMGN4BY Moderate Antagonize the effect of Spironolactone when combined with Flurbiprofen. Rheumatoid arthritis [FA20] [23]
Fenoprofen DML5VQ0 Moderate Antagonize the effect of Spironolactone when combined with Fenoprofen. Rheumatoid arthritis [FA20] [23]
Tolmetin DMWUIJE Moderate Antagonize the effect of Spironolactone when combined with Tolmetin. Rheumatoid arthritis [FA20] [23]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Spironolactone and Quetiapine. Schizophrenia [6A20] [19]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Spironolactone and Mesoridazine. Schizophrenia [6A20] [19]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Spironolactone and Thioridazine. Schizophrenia [6A20] [19]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Spironolactone and Aripiprazole. Schizophrenia [6A20] [19]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Spironolactone and Iloperidone. Schizophrenia [6A20] [19]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Spironolactone and Paliperidone. Schizophrenia [6A20] [19]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Spironolactone and Haloperidol. Schizophrenia [6A20] [19]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Spironolactone and Perphenazine. Schizophrenia [6A20] [19]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Spironolactone and Molindone. Schizophrenia [6A20] [19]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Spironolactone and Chlorpromazine. Schizophrenia [6A20] [19]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Spironolactone and Thiothixene. Schizophrenia [6A20] [19]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Spironolactone and Trifluoperazine. Schizophrenia [6A20] [19]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Spironolactone and Risperidone. Schizophrenia [6A20] [19]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Spironolactone and Amisulpride. Schizophrenia [6A20] [19]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Spironolactone and Asenapine. Schizophrenia [6A20] [19]
Larotrectinib DM26CQR Moderate Decreased metabolism of Spironolactone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [30]
Docetaxel DMDI269 Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [45]
Taxol DMUOT9V Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Taxol. Solid tumour/cancer [2A00-2F9Z] [45]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Spironolactone caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [30]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Spironolactone due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [46]
Apixaban DM89JLN Moderate Decreased metabolism of Spironolactone caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [17]
Tacrolimus DMZ7XNQ Major Increased risk of hyperkalemia by the combination of Spironolactone and Tacrolimus. Transplant rejection [NE84] [47]
Trimethoprim DMM7CHK Major Increased risk of hyperkalemia by the combination of Spironolactone and Trimethoprim. Urinary tract infection [GC08] [48]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Spironolactone and Methdilazine. Vasomotor/allergic rhinitis [CA08] [19]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Spironolactone and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [49]
⏷ Show the Full List of 130 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Docusate sodium E00563 23673837 Surfactant
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Calcium sulfate dihydrate E00315 24928 Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Spironolactone 100 mg tablet 100 mg Oral Tablet Oral
Spironolactone 25 mg tablet 25 mg Oral Tablet Oral
Spironolactone 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Spironolactone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2875).
3 Spironolactone in Covid-19 Induced ARDS
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology. 2011 Jul 11;285(1-2):18-24. doi: 10.1016/j.tox.2011.03.015. Epub 2011 Apr 1.
8 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
9 Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
10 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
11 Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
12 Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study. Hypertension. 1980 Sep-Oct;2(5):672-9. doi: 10.1161/01.hyp.2.5.672.
13 Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58. [PMID: 16373465]
14 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
15 Product Information. Aldactone (spironolactone). Searle, Skokie, IL.
16 Multum Information Services, Inc. Expert Review Panel.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
19 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
20 Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
21 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
23 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
24 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
25 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
26 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
27 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
28 Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
29 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
30 Cerner Multum, Inc. "Australian Product Information.".
31 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
32 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
33 Product Information. Midamor (amiloride). Merck & Co, Inc, West Point, PA.
34 Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
35 Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
36 McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70. [PMID: 5410663]
37 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
38 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
39 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
40 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
41 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
42 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
43 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
44 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
45 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
46 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
47 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
48 Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
49 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.